Sentences with phrase «discount in the stock price»

That means that every dollar of sales for Peabody Energy is selling at a 30 percent discount in the stock price.

That means that the assets of BlackBerry are at more than a 40 percent discount in the stock price.

That means that each dollar of sales for BP is going at more than a 60 % discount in the stock price.

Not exact matches

Important factors that could cause actual results to differ materially from those reflected in such forward - looking statements and that should be considered in evaluating our outlook include, but are not limited to, the following: 1) our ability to continue to grow our business and execute our growth strategy, including the timing, execution, and profitability of new and maturing programs; 2) our ability to perform our obligations under our new and maturing commercial, business aircraft, and military development programs, and the related recurring production; 3) our ability to accurately estimate and manage performance, cost, and revenue under our contracts, including our ability to achieve certain cost reductions with respect to the B787 program; 4) margin pressures and the potential for additional forward losses on new and maturing programs; 5) our ability to accommodate, and the cost of accommodating, announced increases in the build rates of certain aircraft; 6) the effect on aircraft demand and build rates of changing customer preferences for business aircraft, including the effect of global economic conditions on the business aircraft market and expanding conflicts or political unrest in the Middle East or Asia; 7) customer cancellations or deferrals as a result of global economic uncertainty or otherwise; 8) the effect of economic conditions in the industries and markets in which we operate in the U.S. and globally and any changes therein, including fluctuations in foreign currency exchange rates; 9) the success and timely execution of key milestones such as the receipt of necessary regulatory approvals, including our ability to obtain in a timely fashion any required regulatory or other third party approvals for the consummation of our announced acquisition of Asco, and customer adherence to their announced schedules; 10) our ability to successfully negotiate, or re-negotiate, future pricing under our supply agreements with Boeing and our other customers; 11) our ability to enter into profitable supply arrangements with additional customers; 12) the ability of all parties to satisfy their performance requirements under existing supply contracts with our two major customers, Boeing and Airbus, and other customers, and the risk of nonpayment by such customers; 13) any adverse impact on Boeing's and Airbus» production of aircraft resulting from cancellations, deferrals, or reduced orders by their customers or from labor disputes, domestic or international hostilities, or acts of terrorism; 14) any adverse impact on the demand for air travel or our operations from the outbreak of diseases or epidemic or pandemic outbreaks; 15) our ability to avoid or recover from cyber-based or other security attacks, information technology failures, or other disruptions; 16) returns on pension plan assets and the impact of future discount rate changes on pension obligations; 17) our ability to borrow additional funds or refinance debt, including our ability to obtain the debt to finance the purchase price for our announced acquisition of Asco on favorable terms or at all; 18) competition from commercial aerospace original equipment manufacturers and other aerostructures suppliers; 19) the effect of governmental laws, such as U.S. export control laws and U.S. and foreign anti-bribery laws such as the Foreign Corrupt Practices Act and the United Kingdom Bribery Act, and environmental laws and agency regulations, both in the U.S. and abroad; 20) the effect of changes in tax law, such as the effect of The Tax Cuts and Jobs Act (the «TCJA») that was enacted on December 22, 2017, and changes to the interpretations of or guidance related thereto, and the Company's ability to accurately calculate and estimate the effect of such changes; 21) any reduction in our credit ratings; 22) our dependence on our suppliers, as well as the cost and availability of raw materials and purchased components; 23) our ability to recruit and retain a critical mass of highly - skilled employees and our relationships with the unions representing many of our employees; 24) spending by the U.S. and other governments on defense; 25) the possibility that our cash flows and our credit facility may not be adequate for our additional capital needs or for payment of interest on, and principal of, our indebtedness; 26) our exposure under our revolving credit facility to higher interest payments should interest rates increase substantially; 27) the effectiveness of any interest rate hedging programs; 28) the effectiveness of our internal control over financial reporting; 29) the outcome or impact of ongoing or future litigation, claims, and regulatory actions; 30) exposure to potential product liability and warranty claims; 31) our ability to effectively assess, manage and integrate acquisitions that we pursue, including our ability to successfully integrate the Asco business and generate synergies and other cost savings; 32) our ability to consummate our announced acquisition of Asco in a timely matter while avoiding any unexpected costs, charges, expenses, adverse changes to business relationships and other business disruptions for ourselves and Asco as a result of the acquisition; 33) our ability to continue selling certain receivables through our supplier financing program; 34) the risks of doing business internationally, including fluctuations in foreign current exchange rates, impositions of tariffs or embargoes, compliance with foreign laws, and domestic and foreign government policies; and 35) our ability to complete the proposed accelerated stock repurchase plan, among other things.

«We did face supply chain challenges last year, but the full - price channels in North America are now clean,» Edwards said in emailed answers to questions from Reuters, referring to new stock that would not have to be discounted.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

It was, in fact, the ultimate value stock because the discounted present value of the actual, real future cash earnings was far greater than the stock price at the time.

According to MSCI data, Eurozone stocks are currently at a 40 % discount, in price - to - book terms, to the U.S., which looks good compared to the long - term average of approximately 35 %.

Immediately after this offering of shares of our common stock at an assumed initial public offering price of $ per share, the midpoint of the price range listed on the cover of this prospectus, after deducting underwriting discounts and estimated offering expenses payable by us and the application of such net proceeds as described under «Use of Proceeds» elsewhere in this prospectus, Cyrus Capital and the Virgin Group will beneficially own approximately % and % of our outstanding voting common stock.

Our principal stockholders, funds affiliated with or related to Cyrus Capital Partners, L.P. (which we refer to in this prospectus collectively as «Cyrus Capital») and affiliates of Virgin Group Holdings Limited (which we refer to in this prospectus collectively as the «Virgin Group»), as selling stockholders, have granted the underwriters an option to purchase up to additional shares of common stock at the initial public offering price less the underwriting discount solely to cover overallotments.

Millions of Americans own stock in their employer through various employee stock ownership plans and 401 (k) plans.1 While there can be discounted prices and specific tax benefits to buying employer stock, many investors hold way too much of it.

Take advantage of discounted pricing on your company's stock, but don't only invest in your company.

Berkshire received above - market interest payments on the loans and in addition got stock warrants, giving it the right to buy stock at deeply discounted current prices.

In addition, Dropbox has granted the underwriters a 30 - day option to purchase up to 5,400,000 additional shares of Class A common stock at the initial public offering price less underwriting discounts.

At Valuentum, we often use a discounted cash - flow model as a means to back into the current share price of firms in order to ascertain whether the market is unfairly pricing their stock relative to reasonable long - term growth and profitability assumptions.

The net balance sheet position is captured in a discounted cash - flow process, but it is not readily apparent in any PE multiple assessment that only considers a firm's stock price and its earnings per share.

In investing, a defensible position is a strong, well - managed, highly profitable company with a pristine balance sheet and very little debt, and a stock price that trades at reasonable (or discount) valuations.

The debt component of the offering consists of $ 6 million in non-interest bearing non-convertible original issue discount senior secured debt maturing on February 10, 2019 and warrants to purchase a total of 6,875,000 shares of Common Stock at a fixed exercise price of $ 0.96 per share.

A leader in compression therapy products, the company uses high - quality synthetic materials to keep your garments functional for longer - and with our huge selection and competitive prices, there's no better place to buy Juzo's casual and fashion - forward products than Discount Surgical Stockings!

Shopbop has just a few sizes left, but good old Nordstrom is automatically matching the 25 % off (discounted price is already reflected in the item listing) with a full range of sizes in stock.

Discount is reflected in pricing and excludes final sale and out of stock items.

Skiff has formed a relationship with Sprint and Samsung which means most Sprint stores will have this in stock, making purchase and discounts on the unit with a long term 3G package may lower the price drastically for citizens of the USA.

Considering I can get another Pandigital Novel (white, which has better specs than the black) from Kohl's this weekend (if in stock) for about $ 5 more after discounts / price - match with OfficeMax / rebate, I would much rather do that for an ereader bigger than my Archos 5, with a lot of Android capabilities such as Nook, Kindle and Borders apps that will do the decryption for me and have the wifi for direct downloads (and the music player will work ok, although some PDN owners with better hearing have complained about the sound quality).

John Bogle's modified version of the Gordon Equation (or the Dividend Discount Model) is that the total return from stocks equals the investment return plus the speculative return, where Investment Return = Dividend Yield + Earnings Growth Rate and Speculative Return = the change in the price to earnings ratio over the period examined.

When you invest in the Ensemble Fund, you are investing in a collection of strong companies that we believe have competitively advantaged business models, talented management teams, understandable businesses and whose stock prices trade at a discount to their intrinsic value.

In light of Zynga's (ZNGA) rapid descent from its IPO (the stock trades at a 48 % discount to its IPO price), this company may have a unique diamond in the rougIn light of Zynga's (ZNGA) rapid descent from its IPO (the stock trades at a 48 % discount to its IPO price), this company may have a unique diamond in the rougin the rough.

Prior to our intervention, Avigen's stock traded at a mere 33 % of the cash in the bank and at a steep discount to its current price.

A dividend reinvestment plan is an equity investment option from a company that allows to elect your dividends as a way to repurchase more common stock in the company at a discounted price.

Apple stock trades at a price - to - earnings ratio around 10.5, a huge discount versus the average company in the S&P 500 index and its P / E ratio in the neighborhood of 19.

Here, in this article, we list down 10 best discount stock brokers in India that offer reasonable value to its clients, not just in pricing but in multiple facets of stock trading.

Stock quotes DLR 1 - Log in to my Discount Broker 2 - Bid on a limit order at the current Ask price = 10.44 If the order got executed, call broker to move my DLR to my USD account 3 - If allowed right away or wait for 3 days, then sell My DLR at current Bid Price =price = 10.44 If the order got executed, call broker to move my DLR to my USD account 3 - If allowed right away or wait for 3 days, then sell My DLR at current Bid Price =Price = 9.95

For instance, most furniture stores get new merchandise in February and August, so they're looking to clear out old stock at discount prices.

Discounts: In addition to no - fee dividend reinvestment, some companies also offer DRIPs that allow investors to purchase stock at a discount to the current market price.

According to MSCI data, Eurozone stocks are currently at a 40 % discount, in price - to - book terms, to the U.S., which looks good compared to the long - term average of approximately 35 %.

In other words, I bought the stock at a 2.1 % discount to its share price on Friday when I placed the trade.

A mutual fund that focuses on stocks from companies that are typically found in low - growth or mature industries, often produce higher and more regular dividend income, and sell at discounted prices.

Unlike Berkshire - Hathaway, the various common stocks in the portfolio are priced at meaningful discounts from readily ascertainable NAVs.

In contrast, the common stocks of most Hong Kong and Chinese income producing real estate companies are priced at least at 30 % discounts from NAV and usually around 2x to 6x latest 12 month reported earnings.

If so, there are likely to continue to be opportunities for TAVF to invest in the common stocks of well - financed companies at prices that reflect meaningful discounts from NAVs.

Such growth seems a good prospect, based not only on the long - term track records of the companies in various TAM portfolios but, more importantly, assuming that the independent appraisals represent reasonable estimates of future cash flows for existing properties, then future cash flows should be relatively large compared to the current discount market prices for the relevant common stocks.

The OPMI market seems efficient enough most of the time that large discounts from NAV indicate an absence of catalysts that could result in dramatic near - term price appreciation for a common stock, e.g., a contest for control.

A majority of the Fund's equity investments are in the common stocks of companies that are extremely well capitalized and which have been acquired at prices that represent meaningful discounts from readily ascertainable NAVs.

If you are in the mood for a discount, you can purchase both as a bundle for the sale price of $ 19.99: «My Ten Largest Investments + Sainted Seven Stocks Bundle ``.

The principal way that the Fund attempts to put the odds in its favor is by acquiring the common stocks of well - financed companies at prices that represent meaningful discounts from readily ascertainable net asset values.

For the NAV investments at discount prices, long - term performance ought to be good enough if the issuer can continue to increase NAV, or if the company engages in resource conversion activities such as getting taken over, liquidating assets, or buying back common stock on a massive scale.

The impact on stock price of course is also a major factor and not one to discount; even a company issuing non-voting stock has a fiduciary responsibility to act in the interest of those non-voting shareholders, and so should not excessively dilute their value.

That means that each dollar of sales for ConAgr is priced in the stock at more than a one - quarter discount.

Most companies will offer a discount in the range of 10 to 15 % off their stock price at the beginning or end of a 6 - or 12 - month period (whichever price is lower).

You have to remember to sell when you get the new shares, and your taxes become a bit more complicated; the discount that you receive is taxed as ordinary income, and then any change in the price of the stock between when you receive it and you sell it will be considered a capital gain or loss.

It is the same type of analysis used in the Discounted Cash Flow (DCF) method for analyzing stock prices or other investment opportunities.